Insights into Drug Discovery and Development 2025

Here we interview our Director of Medicinal Chemistry, Anita Wegert, for her insights into drug discovery and development for 2025. This interview was conducted an interviewer from the Drug Discovery and Development Europe event and we were able to share our expertise. Curious how our insights can help your next project?

Read more

Symeres and Yoneda Labs Use AI to Optimize Cross-Coupling Reactions

San Francisco, May 29, 2025 – Yoneda Labs, a leader in computational tools for reaction optimization, has successfully collaborated with Symeres, a leading transatlantic, small molecule contract research and manufacturing organization. The aim was to optimize transition metal catalyzed cross-coupling reactions to improve reaction yield and efficiency utilizing Yoneda Labs’ cutting-edge software.

Read more

J. Med. Chem. Publication: Development of a 1,2,4-Triazole-Based Lead Tankyrase Inhibitor: Part II

In this follow-up article, co-published with Oslo University Hospital, we report further development and optimization of 1,2,3-triazole-based tankyrase inhibitors. Through X-ray crystallography supported SAR analysis, we synthesized a series of novel TNKS inhibitors with improved ADME/PK profiles, exhibiting antiproliferative efficacy in colorectal cancer cell lines. Click on the link below for a short summary of this publication.

Read more

Meet the Organix Director, Mario Gonzalez

We are pleased to share a conversation with Dr. Mario Gonzalez, a Director at Organix, as he reflects on his journey from Argentina to Massachusetts and provides valuable career insights in celebration of his 30 years with the company.

Read more

New Production Lines D1 and D2 at our Prague site!

The new production lines D1 and D2 were launched for the first time in May 2024 at the Prague site. The first batch of 11 kg of API was produced in the following weeks, and the tremendous efforts of the many people involved in planning the entire production line have finally paid off. Since the production line was launched, all equipment has been continuously utilized.

Read more

Reliable Tablet Formulation at Exemplify!

We at Symeres pride ourselves on a stellar track record in drug-substance development. For our clients that are looking to rapidly move through phase-appropriate clinical tablet formulation development, Exemplify is the perfect place to start for small-scale to large-scale pharma companies. Our cGMP suites are specially equipped to support everything from pre-tox formulation to first-in-human (FIH) trials and commercially ready formulation.

Read more

Peter Molenveld’s 25th Anniversary with Symeres

Recently, our colleague Peter Molenveld celebrated his 25th anniversary with Symeres. Peter participated in an interview where he shared about his time with Symeres and his growth here as a chemist to leadership within the organization, as well as about his role as secretary at the Royal Netherlands Chemical Society (KNCV).

Read more

New NMR Technology – Meet “Maggie”

Nuclear Magnetic Resonance (NMR) Spectroscopy is a powerful analytical tool well known to all organic chemists and to anyone that works in pharmaceuticals. By placing a sample dissolved in deuterated solvent into a strong magnetic field (roughly 4000x the strength of Earth’s magnetic field) and pulsing it with radio frequencies, the chemist is given an enormous amount of information from the identity and placement of functional groups to relative stereochemistry of diastereomers. Recently, Exemplify added NMR to our expanding list of capabilities.

Read more

Symeres announces leadership evolution

Symeres announces the evolution of its leadership team ahead of the company’s next phase of development. After nearly three decades at the helm, Symeres’ co-founders, Dr. Eelco Ebbers (CEO) and Dr. Frank Leemhuis (Head of Corporate Development), have decided to step back from their current executive roles.

Read more

Official opening of new Oncolines home, the Marie Curie Building at the Pivot Park in Oss, The Netherlands

After months of dedication and collaboration, the official opening of the Marie Curie building at the Pivot Park in Oss was opened on Sep 19th, 2024. The Marie Curie building is a multitenant laboratory building which houses Oncolines B.V., the in vitro biology services laboratory of Symeres. Read more about this exciting development!

Read more

J. Med. Chem. Publication: Preclinical Lead Optimization of a 1,2,4-Triazole-Based Tankyrase Inhibitor

In collaboration with Oslo University Hospital, we report the synthesis and biological activity of novel 1,2,3-triazole-based tankyrase inhibitors. Through a modular synthetic pathway and X-ray crystallography supported SAR analysis, we synthesized a series of novel TNKS inhibitors with improved ADME profiles, exhibiting antiproliferative efficacy in colorectal cancer cell lines. Click on the link below for a short summary of this publication.

Read more

New video of our Solid-State Center of Excellence

In this new video our colleagues Gabriella Pizutti, Chantalle van Berkel, and Eva Verhofstad, will give you an exciting lab tour through the Symeres Solid-State Centre of Excellence, located at the Symeres site in Weert, the Netherlands. You will learn more about PhysChem Properties, Solid Form Screening, Crystallization, Crystal Habit, Pre-formulation, and Formulation. Feel free to contact us via the contact form on this website if you would like to learn more about our Solid-State capabilities.

Read more

New equipment at Exemplify

Exemplify has recently acquired a Mettler-Toledo EasyMax 402 automated reactor system to add to its process development capabilities. This instrument can accommodate reactor sizes of 100 and 400 mL and allows for the precise automated control of reaction parameters such as temperature, stirring speed, reagent addition rate, and pH, providing real-time data collection that can greatly enhance our understanding of a reaction’s unique profile.

Read more

New 100 L vessels in Groningen

The first of the two new 100 L glass-lined stainless steel reactor lines has successfully finished the testing and now it is operational at our Groningen site. By doubling our batch size capacity, we have increased the efficiency for large-scale non-GMP production projects. This will result in faster delivery times for our clients and less batch routine work for our chemists.

Read more

Organix: New facility

On March 26th we had the Grand Opening of our brand new, state-of-the-art Organix synthetic and analytical chemistry laboratories in Woburn, just outside Boston MA.

Read more

Towards Multitargeted Ligands as Pain Therapeutics: Dual Ligands of the Cavα2δ-1 Subunit of Voltage-Gated Calcium Channel and the μ-Opioid Receptor

In collaboration with WeLab Barcelona, we report the synthesis and biological activity of novel pain therapeutics, which target both Cavα2δ-1 and MOR. One of these disubstituted pyrrolidines demonstrated an analgesic effect in various rodent models of pain, and a lack of unfavorable off-target interactions, showing no evident signs of withdrawal or tolerance. Click on the link below for a short summary of this publication.

Read more

Innovative macrocycles as powerful Mcl-1 inhibitors

This is a recap of the article “Development of potent Mcl-1 inhibitors: structural investigations on macrocycles originating from a DNA-encoded chemical library screen” published in the Journal of Medicinal Chemistry. Myeloid cell leukemia 1 (Mcl-1) is a protein that plays a crucial role in the regulation of cell survival and cell death. It is part of a family of proteins called the Bcl-2 family, which are known for their involvement in controlling the life span of cells.

Read more

Oncolines unveils new State-of-the-Art Laboratories

In a significant stride towards advancing cancer research and drug development, Oncolines, has officially received the keys to its new laboratories and offices situated within the prestigious Curie Building on the Pivot Park in Oss, the Netherlands.

Read more

Our Article Published in the Journal of Medicinal Chemistry

Symeres is thrilled to announce the publication of a scientific article in the prestigious Journal of Medicinal Chemistry with our colleague Koen Hekking as the main author and many more Symerians involved! We are incredibly proud of our colleagues who were instrumental in the research and development of this innovative project.

Read more

Peter Molenveld Assumes Role as Secretary of KNCV (Royal Netherlands Chemical Society)

Symeres is proud to announce that our colleague Dr. Peter Molenveld has been appointed as a board member of the Royal Netherlands Chemical Society (KNCV). His appointment as Secretary marks a crucial milestone in Molenveld’s career and signifies his commitment to advancing the interests of the chemical community in the Netherlands.

Read more

Interview with the Computer-Aided Drug Design (CADD) Department

Our Computer Aided Drug Design department supports our clients’ drug discovery projects with some of the best (predictive) software.

Read more

“If the compound can be made, Symeres will undoubtedly find out a good way to make it.” Dooyoung Jung, CEO of Pinotbio.

An in-depth interview with Doo Young Jung, the founder and CEO of our client Pinotbio in South Korea, focused on the challenge of cancer resistance/relapse

Read more

New scientific services from Symeres

We’re proud to announce that our brand new CMC facility at the Exemplify site of Symeres in New Jersey has been successfully completed. GMP drug product R&D facilities that will allow it to provide end-to-end services ranging from GMP and non-GMP drug product development to phase 1 and 2 clinical supplies of various oral, parenteral, and topical formulation dosage forms.

Read more